survival signalling akt eif4e oncogenesis cancer therapy
evading apoptosis considered hallmark cancer mutations apoptotic regulators invariably accompany tumorigenesis many chemotherapeutic agents induce apoptosis disruption apoptosis tumour evolution can promote drug resistance example akt apoptotic regulator activated many cancers may promote drug resistance vitro nevertheless akt disables apoptosis contribution clinical drug resistance unclear using murine lymphoma model show akt promotes tumorigenesis drug resistance disrupting apoptosis disruption akt signalling using mtor inhibitor rapamycin reverses chemoresistance lymphomas expressing akt apoptotic defects eif4e translational regulator acts downstream akt mtor recapitulates akts action tumorigenesis drug resistance unable confer sensitivity rapamycin chemotherapy results establish akt signalling mtor eif4e important mechanism oncogenesis drug resistance vivo reveal targeting apoptotic programmes can restore drug sensitivity genotype-dependent manner
